Literature DB >> 23611691

Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors.

Yi-Hui Peng1, Hui-Yi Shiao, Chih-Hsiang Tu, Pang-Min Liu, John Tsu-An Hsu, Prashanth Kumar Amancha, Jian-Sung Wu, Mohane Selvaraj Coumar, Chun-Hwa Chen, Sing-Yi Wang, Wen-Hsing Lin, Hsu-Yi Sun, Yu-Sheng Chao, Ping-Chiang Lyu, Hsing-Pang Hsieh, Su-Ying Wu.   

Abstract

The Asp-Phe-Gly (DFG) motif plays an important role in the regulation of kinase activity. Structure-based drug design was performed to design compounds able to interact with the DFG motif; epidermal growth factor receptor (EGFR) was selected as an example. Structural insights obtained from the EGFR/2a complex suggested that an extension from the meta-position on the phenyl group (ring-5) would improve interactions with the DFG motif. Indeed, introduction of an N,N-dimethylamino tail resulted in 4b, which showed almost 50-fold improvement in inhibition compared to 2a. Structural studies confirmed this N,N-dimethylamino tail moved toward the DFG motif to form a salt bridge with the side chain of Asp831. That the interactions with the DFG motif greatly contribute to the potency of 4b is strongly evidenced by synthesizing and testing compounds 2a, 3g, and 4f: when the charge interactions are absent, the inhibitory activity decreased significantly.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23611691     DOI: 10.1021/jm400072p

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  17 in total

1.  Statistical analysis of EGFR structures' performance in virtual screening.

Authors:  Yan Li; Xiang Li; Zigang Dong
Journal:  J Comput Aided Mol Des       Date:  2015-10-17       Impact factor: 3.686

2.  Systematic analysis and molecular profiling of EGFR allosteric inhibitor cross-reactivity across the proto-oncogenic ErbB family kinases by integrating dynamics simulation, energetics calculation and biochemical assay.

Authors:  Yanli Ma; Bingli Qi; Meiying Ning; Lijuan Zhang; Zeyu An; Jing Zhao
Journal:  Eur Biophys J       Date:  2022-03-21       Impact factor: 1.733

Review 3.  Molecular mechanisms of resistance to kinase inhibitors and redifferentiation in thyroid cancers.

Authors:  Marie-Claude Hofmann; Muthusamy Kunnimalaiyaan; Jennifer R Wang; Naifa L Busaidy; Steven I Sherman; Stephen Y Lai; Mark Zafereo; Maria E Cabanillas
Journal:  Endocr Relat Cancer       Date:  2022-09-14       Impact factor: 5.900

4.  The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents.

Authors:  Xin Zhang; Sudhir Raghavan; Michael Ihnat; Jessica E Thorpe; Bryan C Disch; Anja Bastian; Lora C Bailey-Downs; Nicholas F Dybdal-Hargreaves; Cristina C Rohena; Ernest Hamel; Susan L Mooberry; Aleem Gangjee
Journal:  Bioorg Med Chem       Date:  2014-05-14       Impact factor: 3.641

5.  Apoptosis induction by an analog of curcumin (BDMC-A) in human laryngeal carcinoma cells through intrinsic and extrinsic pathways.

Authors:  Kumaravel Mohankumar; Sankar Pajaniradje; Subhashree Sridharan; Vivek Kumar Singh; Larance Ronsard; Akhil C Banerjea; Benson Chellakkan Selvanesan; Mohane Selvaraj Coumar; Latha Periyasamy; Rukkumani Rajagopalan
Journal:  Cell Oncol (Dordr)       Date:  2014-12-01       Impact factor: 6.730

Review 6.  Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic.

Authors:  Andrew B West
Journal:  Mov Disord       Date:  2014-12-01       Impact factor: 10.338

7.  Structural insights into the polypharmacological activity of quercetin on serine/threonine kinases.

Authors:  Bincy Baby; Priya Antony; Walaa Al Halabi; Zahrah Al Homedi; Ranjit Vijayan
Journal:  Drug Des Devel Ther       Date:  2016-09-27       Impact factor: 4.162

8.  A systematic analysis of atomic protein-ligand interactions in the PDB.

Authors:  Renato Ferreira de Freitas; Matthieu Schapira
Journal:  Medchemcomm       Date:  2017-09-26       Impact factor: 3.597

9.  Discovery of a series of novel phenylpiperazine derivatives as EGFR TK inhibitors.

Authors:  Juan Sun; Xin-Yi Wang; Peng-Cheng Lv; Hai-Liang Zhu
Journal:  Sci Rep       Date:  2015-09-09       Impact factor: 4.379

10.  Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent.

Authors:  Wei Liu; Jin-Feng Ning; Qing-Wei Meng; Jing Hu; Yan-Bin Zhao; Chao Liu; Li Cai
Journal:  Drug Des Devel Ther       Date:  2015-07-23       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.